CDKL5 Deficiency Disorder market size in the 7MM was found to be USD 6.54 Million in 2020. The market size is expected to increase owing to the extensive research and development activities of pharmaceutical companies and the expected launch of therapies such as TAK-935/OV935 (Takeda and Ovid Therapeutics) and Ganaxolone (Marinus Pharmaceuticals).
DelveInsight’s “Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder: An Overview
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by changes (mutations) in the CDKL5 gene. CDD has been classified as a DEE because the genetic change causes both epileptic activities as well as severe impairment of development. Previously known as serine/threonine-protein kinase 9 (STK9), CDKL5, and mutations in this gene were first identified as disease-causing in 2004.
The hallmarks of CDD are the onset of seizures at a very early age (usually about 3 months but can be as early as the first week of life) and severe neurodevelopmental delay impacting cognitive, motor, speech, and visual function. CDD can manifest in a broad range of clinical severity and is often associated with other symptoms such as gastrointestinal and sleep disturbances.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Key Facts
As per the NORD, CDKL5 mutations have been identified in many ethnic groups, with more females than males being reported with an approximate ratio of 4:1.
As per DelveInsight’s estimation, there were 16,511+ prevalent cases of CDKL5 in the 7MM in 2020. Out of this, the US contributed the maximum number of cases (6,138 in 2020).
In EU-5, Germany has the highest number of diagnosed cases, i.e., 600+, followed by Italy with 390+ cases and France with 280+ cases. While Spain has the least number of cases, with 190+ in 2020.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted CDKL5 Deficiency Disorder market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the CDKL5 Deficiency Disorder market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Segmentation
Total Prevalent Population of CDKL5 Deficiency Disorder
Gender-specific Prevalence of CDKL5 Deficiency Disorder
Clinical Manifestation Specific Prevalence of CDKL5 Deficiency Disorder
Diagnosed and Treatable Prevalence of CDKL5 Deficiency Disorder
Treated cases of CDKL5 Deficiency Disorder
Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CDKL5 Deficiency Disorder market or expected to get launched during the study period. The analysis covers the Cyclin-Dependent Kinase-Like 5 Deficiency Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the CDKL5 Deficiency Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Some of the key companies in the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Market include:
Takeda
Ovid Therapeutics
Ganaxolone
Marinus Pharmaceuticals
Zogenix
PTC Therapeutics
And many others
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Therapies covered in the report include:
Ganaxolone – Ganaxolone, developed by Marinus Pharmaceuticals, is an allosteric modulator of GABAA receptors acting through binding sites, which are distinct from the benzodiazepine binding site. It has activity in a broad range of animal models of epilepsy.
TAK-935/OV935 – Soticlestat (TAK-935/OV935) is a potent, highly-selective, first-in-class inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H) being investigated as an anti-epileptic drug (AED).
ZX008 (fenfluramine hydrochloride) – Zogenix is developing ZX008. It is a low-dose, oral solution formulation of fenfluramine, a small molecule with unique serotogenic and positive sigma-1 receptor modulation activity, approved in the US for treating seizures associated with Dravet syndrome in patients 2 years of age and older.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Competitive Intelligence Analysis
4. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Overview at a Glance
5. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Disease Background and Overview
6. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Patient Journey
7. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Treatment Algorithm, Current Treatment, and Medical Practices
9. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Unmet Needs
10. Key Endpoints of Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Treatment
11. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Marketed Products
12. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Emerging Drugs and Latest Therapeutic Advances
13. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Seven Major Market Analysis
14. Attribute Analysis
15. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Outlook (In US, EU5, and Japan)
16. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Access and Reimbursement Overview
17. KOL Views on the Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market
18. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Drivers
19. Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
Other Trending Healthcare Reports By DelveInsight
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Pipeline Insights
“Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the CDKL5 Deficiency Disorder market.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
